IR Pharma company logo
  • Company overview
  • Meet the team
  • Why we're different;
  • Technology - The drug development process at IRP; The Drug Evaluation Process; Model systems
  • Portfolio
  • Contact us

  • We always adopt a collaborative approach


    IR Pharma will have a presence
    at the following conferences.
    Contact us to arrange
    a meeting with one of the team.

    May 19-24, 2017
    American Thoracic Society
    Annual Conference.
    Washington DC, USA.

    September 9-13, 2017
    European Respiratory Society
    Milan, Italy.

    Contact us

    IR Pharma
    National Heart & Lung Institute
    1st floor,
    Sir Alexander Fleming Building,
    Imperial College,
    London SW7 2AZ.
    T: +44 (0)20-7594 8579

    Rapid response,
    positive impact

    At IR Pharma, we fully understand the difficulties associated with evaluating and developing new treatments and drugs. When working with clients on any project, no matter how routine and regardless of company size, we always adopt a collaborative approach.

    The initial step in such a collaboration involves understanding a potential client's needs.

    This will initiate a rapid response from our business management team (all have life-science research backgrounds), who, without obligation, will make contact to establish an outline of your requirements.

    Naturally, we fully respect confidentiality - even at this early stage, we are happy to accommodate and formalise arrangements through CDA.

    Once we have a reasonable outline of your needs, details will be forwarded to our scientific team for an initial assessment and comments on the investigational studies that appear relevant.

    This information will be relayed back to the potential client with a view to a more detailed follow-on discussion concerning the next steps and how IR Pharma can assist in the development of your product.

    If you require support and assistance with the pre-clinical assessment of your product, contact IR Pharma. You can be confident we can make a positive impact on your discovery requirements.